Highlights Merck & Co., Inc.

Stocks

MRK

US58933Y1055

Pharmaceuticals

Market Closed - NYSE Other stock markets 16:00:51 2026-06-12 EDT			5-day change	1st Jan Change
119.05 ^USD	-1.42%		-1.44%	+13.10%

06-12	Merck Wins FDA Approvals for Keytruda Combination in Kidney Cancer	DJ
06-12	Merck Receives Fda Approval for KEYTRUDA, KEYTRUDA QLEX, and WELIREG Combinations for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma	CI

Highlights

06-12	Merck Receives Fda Approval for KEYTRUDA, KEYTRUDA QLEX, and WELIREG Combinations for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma	CI
06-11	Merck Bolsters Animal-Health Unit With Deal to Buy Targan	DJ
06-11	Merck to Acquire Poultry Biodevice Firm Targan to Expand Animal Health Tech	MT
06-11	Merck to Acquire Poultry Biodevice Firm Targan to Expand Animal Health Tech	MT
06-09	Cancer vaccines based on mRNA advance, despite US cuts	RE
06-08	Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment	CI
06-08	Merck and Gilead Sciences, Inc. Provides Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study	CI
06-04	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases	MT
06-04	Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports	MT
06-02	Agilent Gets US FDA Clearance for Expanded Use of Cancer Test on Dako Omnis Platform	MT
05-29	Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation	CI
05-26	Merck Co Inc declares Q3 2026 dividend of $0.85 per share	RE
05-26	Merck Keeps Quarterly Dividend at $0.85 a Share, Payable July 8 to Holders of Record June 15	MT
05-26	Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2026, Payable on July 8, 2026	CI
05-26	Adcendo ApS and MSD Enter Clinical Collaboration and Supply Agreement to Evaluate ADCE-T02 in Combination with KEYTRUDA (Pembrolizumab) in Phase Ib Study in Patients with Advanced Solid Tumors	CI
05-22	Merck's Keytruda, Padcev Combination to Treat Bladder Cancer Receives Positive EU Recommendation; Shares Up Pre-Bell	MT
05-22	Merck & Co., Inc. Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer	CI
05-22	EMA's CHMP recommends extension to marketing authorisation for Wegovy	RE
05-21	Moderna, Merck cancer combo cuts melanoma spread risk at five years	RE
05-19	Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer	CI
05-18	Merck's drug helps uterine cancer patients live longer in late-stage trial	RE
05-18	Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer	CI
05-18	Regeneron drops after skin cancer treatment misses late-stage trial goal	RE
05-12	Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026	CI
05-05	Merck Completes Terns Pharmaceuticals Acquisition	MT